Keywords: Post-myocardial infarction, Mortality risks, Bayer, Xarelto, Decision Resources, Bleeding, US Cardiologists
Reduced incidence of mortality is greatest unmet need in post-myocardial infarction, say US cardiologists and MCOs
Article | 18 June 2012
According to insights from US cardiologists and managed care organization (MCO) pharmacy directors surveyed by advisory firm Decision Resources, the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
